The BCMA CAR-T co-developed by Innovent and IASO was granted breakthrough therapy designation by the NMPA for the treatment of relapsed/refractory multiple myeloma

Innovent Biologics

22 February 2021 - Innovent Biologics today jointly announce that the Center for Drug Evaluation of China's National Medical Products Administration has granted breakthrough therapy designation for the investigational chimeric antigen receptor-T cell therapy co-developed by Innovent and IASO for treatment of relapsed/refractory multiple myeloma.

The breakthrough therapy designation for IBI326 is based on the results observed in ongoing Phase 1/2 study for the treatment of adults with relapsed or refractory multiple myeloma being conducted in China.

Read Innovent Biologics press release 

Michael Wonder

Posted by:

Michael Wonder